Jim Miller

An innovative approach to capacity management.

Is the contract-only CMO an endangered species?

Measuring the size of the market for contract manufacturing services requires a careful hand.

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Service providers must focus on delivering a superior customer experience.

The evolving bio/pharmaceutical business model poses risk for CMOs.

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.